A3P Biomedical raises SEK 110 million in growth capital
A3P Biomedical announced today that it has raised SEK 110 million in growth capital from institutional and private investors in Sweden to fund the commercialization of Stockholm3, A3P’s superior prostate cancer test. Near-term, A3P will focus on accelerating the Nordic launch, as well as preparing commercialization in Europe and North…